217 related articles for article (PubMed ID: 16569357)
41. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
[TBL] [Abstract][Full Text] [Related]
42. DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44-60).
Pokorna D; Cerovska N; Smahel M; Moravec T; Ludvikova V; Mackova J; Synkova H; Duskova M; Hozak P; Veleminsky J
Oncol Rep; 2005 Oct; 14(4):1045-53. PubMed ID: 16142370
[TBL] [Abstract][Full Text] [Related]
43. DNA vaccines against HPV-16 E7-expressing tumour cells.
De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A
Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408
[TBL] [Abstract][Full Text] [Related]
44. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects.
Wang-Johanning F; Gillespie GY; Grim J; Rancourt C; Alvarez RD; Siegal GP; Curiel DT
Cancer Res; 1998 May; 58(9):1893-900. PubMed ID: 9581830
[TBL] [Abstract][Full Text] [Related]
45. Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice.
Gérard CM; Baudson N; Kraemer K; Ledent C; Pardoll D; Bruck C
Clin Cancer Res; 2001 Mar; 7(3 Suppl):838s-847s. PubMed ID: 11300481
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death.
Kim TW; Hung CF; Juang J; He L; Hardwick JM; Wu TC
Gene Ther; 2004 Feb; 11(3):336-42. PubMed ID: 14737094
[TBL] [Abstract][Full Text] [Related]
47. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
Herd KA; Harvey T; Khromykh AA; Tindle RW
Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
[TBL] [Abstract][Full Text] [Related]
48. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
49. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
[TBL] [Abstract][Full Text] [Related]
50. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination.
Michel N; Osen W; Gissmann L; Schumacher TN; Zentgraf H; Müller M
Virology; 2002 Mar; 294(1):47-59. PubMed ID: 11886264
[TBL] [Abstract][Full Text] [Related]
51. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
52. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
Lee DW; Anderson ME; Wu S; Lee JH
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
[TBL] [Abstract][Full Text] [Related]
53. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
[TBL] [Abstract][Full Text] [Related]
54. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice.
Eiben GL; Velders MP; Schreiber H; Cassetti MC; Pullen JK; Smith LR; Kast WM
Cancer Res; 2002 Oct; 62(20):5792-9. PubMed ID: 12384540
[TBL] [Abstract][Full Text] [Related]
55. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
[TBL] [Abstract][Full Text] [Related]
56. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
57. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase.
Smahel M; Pokorná D; Macková J; Vlasák J
J Gene Med; 2004 Oct; 6(10):1092-101. PubMed ID: 15386741
[TBL] [Abstract][Full Text] [Related]
58. Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer.
Giannouli C; Brulet JM; Gesché F; Rappaport J; Burny A; Leo O; Hallez S
Anticancer Res; 2003; 23(4):3523-31. PubMed ID: 12926102
[TBL] [Abstract][Full Text] [Related]
59. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
Di Bonito P; Grasso F; Mochi S; Petrone L; Fanales-Belasio E; Mei A; Cesolini A; Laconi G; Conrad H; Bernhard H; Dembek CJ; Cosma A; Santini SM; Lapenta C; Donati S; Muratori C; Giorgi C; Federico M
Virology; 2009 Dec; 395(1):45-55. PubMed ID: 19800648
[TBL] [Abstract][Full Text] [Related]
60. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.
Kim MS; Sin JI
Immunology; 2005 Oct; 116(2):255-66. PubMed ID: 16162274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
